The state of New York currently has 30 active clinical trials seeking participants for Migraine research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/25/2025
Locations: Dent Neurologic Institute, Amherst, New York +1 locations
Conditions: Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/25/2025
Locations: Dent Neurologic Institute, Amherst, New York +1 locations
Conditions: Chronic Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/23/2025
Locations: Rochester Clinical Research, LLC, Rochester, New York
Conditions: Menstrual Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/23/2025
Locations: Dent Neurosciences Research Center, Inc., Amherst, New York +1 locations
Conditions: Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Recruiting
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache day... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Dent Neurosciences Research Center, Inc., Amherst, New York +3 locations
Conditions: Chronic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Recruiting
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches. Migrain... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: SPRI Clinical Trials, LLC, Brooklyn, New York +2 locations
Conditions: Episodic Migraine
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
Recruiting
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will b... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/19/2025
Locations: Montefiore Medical Center: Headache Center, Bronx, New York +2 locations
Conditions: Episodic Migraine, Chronic Migraine
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Recruiting
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age. Atogepant... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/19/2025
Locations: Dent Neurologic Institute - Amherst /ID# 270260, Amherst, New York
Conditions: Chronic Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/18/2025
Locations: Dent Neurosciences Research Center, Amherst, New York +8 locations
Conditions: Acute Treatment of Migraine
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
Recruiting
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 1000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study across the world. Partici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Dent Neurologic Institute - Amherst /ID# 267606, Amherst, New York +1 locations
Conditions: Migraine
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Recruiting
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/17/2025
Locations: Dent Neurosciences Research Center Incorporated, Amherst, New York +1 locations
Conditions: Chronic Migraine in Children
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Recruiting
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2025
Locations: Dent Neurosciences Research Center Incorporated, Amherst, New York +1 locations
Conditions: Migraine